• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Rubius Therapeutics Inc.

    2/27/23 6:51:16 AM ET
    $RUBY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $RUBY alert in real time by email
    S-8 POS 1 tm237887d6_s8pos.htm S-8 POS

    As filed with the Securities and Exchange Commission on February 27, 2023

     

    Registration No. 333-264814

    Registration No. 333-255942

    Registration No. 333-237103

    Registration No. 333-231478

    Registration No. 333-226226

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-264814

     

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-255942

     

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-237103

     

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-231478

     

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-226226

     

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    RUBIUS THERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware 46-2688109
    (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)
       

    c/o Verdolino & Lowey, P.C.

    124 Washington Street, Suite 101

    Foxborough, Massachusetts

    02035
    (Address of Principal Executive Offices) (Zip Code)

     

    Rubius Therapeutics, Inc. Amended and Restated 2014 Stock Incentive Plan

    Rubius Therapeutics, Inc. 2018 Stock Option and Incentive Plan

    Rubius Therapeutics, Inc. 2018 Employee Stock Purchase Plan

    (Full title of the plans)

     

    Dannielle Appelhans

    Chief Executive Officer

    Rubius Therapeutics, Inc.

    c/o Verdolino & Lowey, P.C.

    124 Washington Street, Suite 101

    Foxborough, MA 02035

    (508) 543-1720

    (Name and address of agent for service and telephone number, including area code, of agent for service)

     

    Copies to:

     

    Jacqueline Mercier, Esq.

    Yasin Akbari, Esq.

    Goodwin Procter LLP

    100 Northern Avenue

    Boston, Massachusetts 02210

    (617) 570-1762

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act (Check one):

     

    Large accelerated filer   ¨   Accelerated filer   ¨
           
    Non-accelerated filer   ¨ (Do not check if a smaller reporting company)   Smaller reporting company   x
           
            Emerging growth company   ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

    DEREGISTRATION OF SECURITIES

     

    This Post-Effective Amendment No. 1 (“Post-Effective Amendment No. 1”), filed by Rubius Therapeutics, Inc., a Delaware corporation (the “Company”), removes from registration all shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) registered under the following Registration Statements on Form S-8 filed by the Company (each a “Registration Statement,” and collectively, the “Registration Statements”) with the U.S. Securities and Exchange Commission (the “Commission”), pertaining to the registration of shares of Common Stock offered under certain employee benefit and equity plans and agreements:

     

      • Registration Statement on Form S-8 (No. 333-264814), filed with the Commission on May 10, 2022, pertaining to the registration of 3,152,231 shares of Common Stock of the Company, relating to the Company’s 2018 Stock Option and Incentive Plan (the “2018 Plan”).
         
      • Registration Statement on Form S-8 (No. 333-255942), filed with the Commission on May 10, 2021, pertaining to the registration of 2,431,609 shares of Common Stock of the Company, relating to the 2018 Plan.
         
      • Registration Statement on Form S-8 (No. 333-237103), filed with the Commission on March 12, 2020, pertaining to the registration of 3,200,649 shares of Common Stock of the Company, relating to the 2018 Plan.
         
      • Registration Statement on Form S-8 (No. 333-231478), filed with the Commission on May 15, 2019, pertaining to the registration of 3,169,393 shares of Common Stock of the Company, relating to the Company’s 2018 Plan and 2018 Employee Stock Purchase Plan (the “2018 ESPP”).
         
      • Registration Statement on Form S-8 (No. 333-226226), filed with the Commission on July 18, 2018, pertaining to the registration of 18,621,525 shares of Common Stock of the Company, relating to the 2018 Plan, 2018 ESPP, and the Company’s Amended and Restated 2014 Stock Incentive Plan.

     

    As previously disclosed in a Form 8-K filed with the Commission on February 22, 2023, the board of directors of the Company (the “Board”) approved a plan of liquidation and dissolution of the Company (the “Plan of Dissolution”), subject to the approval of the Company’s stockholders. As a result of the proposed dissolution, the Company has terminated all offerings of its securities pursuant to its existing registration statements, including the Registration Statements. The Company hereby terminates the effectiveness of the Registration Statements and removes and withdraws from registration all securities of the Company registered under the Registration Statements that remain unsold as of the date hereof.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing this Post-Effective Amendment No. 1 to the Registration Statements on Form S-8 and has duly caused this Post-Effective Amendment No. 1 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Foxborough in the Commonwealth of Massachusetts, on February 27, 2023.

     

      RUBIUS THERAPEUTICS, INC.
         
      By: /s/ Dannielle Appelhans
        Name: Dannielle Appelhans
        Title:

    Chief Executive Officer

    (Principal Executive Officer)

     

    Pursuant to the requirements of the Securities Act of 1933, this Post-Effective Amendment No. 1 to the Registration Statements on Form S-8 has been signed by the following person in the capacity and on the date indicated.

     

    Signatures   Capacity   Date

     

    /s/ Pablo Cagnoni

    Pablo Cagnoni

     

     

    Director

     

     

    February 27, 2023

     

    *

    Catherine Sohn

     

     

    Director

     

     

    February 27, 2023

     

    *

    Jonathan R. Symonds

     

     

    Director

     

     

    February 27, 2023

     

     

    * By: /s/ Pablo Cagnoni  
      Pablo Cagnoni  
      Attorney-in-Fact  

     

     

     

    Get the next $RUBY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RUBY

    DatePrice TargetRatingAnalyst
    9/13/2022Buy → Neutral
    Guggenheim
    2/25/2022$14.00 → $5.00Market Perform
    SVB Leerink
    11/9/2021$20.00 → $14.00Market Perform
    SVB Leerink
    10/19/2021$25.00 → $22.00Equal-Weight
    Morgan Stanley
    More analyst ratings